Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study

Table 2 Prevalence of human papilloma virus (HPV) and vaccine covered genotypes among women

Parameter	Frequency*	Proportion	Proportion	Proportion	SE	95% CI
Parameter	Frequency*	(%)^a	(%)^b	(%)^c	SE	Lower	Upper
HPV positive	138	43.5			2.9	37.9	48.6
Type of infection
Single	59	18.6	42.8		2.1	14.2	23.0
Multiple	79	24.9	57.2		2.5	20.2	30.6
Risk category
High risk	111	35.0	80.4		2.8	29.6	40.4
Probable high risk	46	14.5	33.3		2.0	10.7	18.3
Low risk	54	17.0	39.1		2.2	12.9	21.2
High-risk HPV genotype
HPV-16	14	4.4	10.1	12.6	1.2	2.2	6.6
HPV-18	13	4.1	9.4	11.7	1.1	2.2	6.3
HPV-31	12	3.8	8.7	10.8	1.1	1.9	6.3
HPV-33	2	0.6	1.4	1.8	0.5	0.0	1.6
HPV-35	17	5.4	12.3	15.3	1.3	2.8	7.9
HPV-39	10	3.2	7.2	9.0	1.0	1.6	5.4
HPV-45	13	4.1	9.4	11.7	1.1	2.2	6.3
HPV-51	7	2.2	5.1	6.3	0.8	0.6	3.8
HPV-52	58	18.3	42.0	52.3	2.1	14.2	22.4
HPV-56	8	2.5	5.8	7.2	0.9	0.9	4.4
HPV-58	28	8.8	20.3	25.2	1.6	5.7	12.0
HPV-59	6	1.9	4.3	5.4	0.7	0.6	3.5
Probable high-risk HPV genotype
HPV-66	25	7.9	18.1	54.3	1.5	5.3	11.1
HPV-68	26	8.2	18.8	56.5	1.5	5.7	11.4
Low-risk HPV genotype
HPV-6/11	3	0.9	2.2	5.6	0.6	0.0	2.2
HPV-42	30	9.5	21.7	55.6	1.6	6.3	12.9
HPV-43	17	5.4	12.3	31.5	1.3	2.8	8.2
HPV-44	7	2.2	5.1	13.0	0.8	0.6	3.8
Vaccine covered genotypes
HPV 16/18	26	8.2			1.6	5.0	11.7
HPV 6/11/16/18	29	9.1			1.7	6.0	12.6
HPV 6/11/16/18/31/33/45/52/58	90	28.4			2.5	23.3	33.2

*Because of the possibility of multiple infections, women may be counted more than once
^aPercentages calculated using the total number of cases (N=317) as a common denominator
^bPercentages calculated using the number of positive cases (N=138) as a common denominator
^cPercentages calculated using the number of positive cases among the risk category as a common denominator

ISSN: 1472-6874